

Frequency of Helicobacter Pylori Infections and Its Association with Immune Thrombocytopenia in Patients Presenting with Dyspepsia in Tertiary Care Setting, Islamabad

DR Asma Nasrullah(AJKMC MZD)

DR Abid Fareed (PMC Rawalakot)

DR Eisha Mehrban (AJKMC MZD)

DR Bilal HUSSain (Chandka Medical College larkana)

DR Celina S.Hussain (PMC Rawalakot)

DR Muhammad Faisal (SKBZN MC ,Lahore)

DR Haseeb Ahmed (PMC Rawalakot)

ABSTRACT

Objective: To determine the frequency of Helicobacter Pylori (H. Pylori) infection and its association with immune thrombocytopenia in patients presenting with dyspepsia symptoms.

Study Design: Cross-sectional study.

Place and Duration of Study. The study was conducted at the Department of General Medicine, Gastroenterology and Hematology, PIMS Islamabad, Pakistan from 20th October 2022 to 20th April 2026.

Methods. A total of 275 patients with the symptoms of dyspepsia were enrolled. All patients of either sex or any age with the signs and symptoms of dyspepsia presenting through Gastro/Medicine OPD, wards, and emergency and admitted to hospital were included in the study. Those addicted to alcohol, on drugs (NSAIDS, Steroids) without PPI cover, chronic renal failure, and pregnancy were excluded from the study. The primary outcome was to determine the frequency of Helicobacter pylori infection in dyspeptic patients in our local settings.

Results: In this study, out of a total of 275 cases, females presented in dominance with 61%

proportion. The average age of patients was 40 years, ranging from 44 to 95 years. The main

presenting complaints were retrosternal burning (74.4%), bloating (65%), pain in the upper abdomen (49.6%), and water brash (37.9%). The frequency of helicobacter pylori infection confirmed on stool for helicobacter pylori antigen was (64.2%). 30.5% of patients have immune thrombocytopenia among those with stool for helicobacter pylori antigen positive.

Conclusion: Our findings validate previous reports on the association of helicobacter pylori infection with dyspepsia. In our study a high proportion of patients (64.2%) were having helicobacter pylori infection.

Keywords: Dyspepsia, Helicobacter-Pylori Infection, Immune Thrombocytopenia.

Introduction

Dyspepsia was defined as persistent or recurrent

one or more than one of the four cardinal symptoms, namely epigastric pain, epigastric burning, postprandial fullness, and early satiety without any organic cause to explain the

symptoms.¹ It is a wide spectrum of gastro-

intestinal disorders that affects 25% of the population worldwide.² According to Rome III questionnaire, 10.3% patients had dyspepsia; 7.3% patients had postprandial distress, epigastric pain was present in 5.5%, while 24.4%

had all symptoms.³ There is a strong association between Helicobacter Pylori (H-Pylori) and

dyspepsia. Many causes of dyspepsia exist, including Helicobacter Pylori that causes

present in 40% of immunethrombocytopenia
dyspepsia symptoms.⁴ Dyspepsia is more
prevalent in younger age group than older population. It is
more prevalent in women than
men except older than 65 years.⁵ Functional
dyspepsia is a diagnosis of exclusion. More than 60% of
the patients who were investigated for more serious
diseases like peptic ulcer, gastro- esophageal reflux
disease and gastric cancers, the tests results are
normal and the diagnosis was functional
dyspepsia.⁶ Helicobacter Pylori (H-Pylori) is
associated with chronic gastritis, peptic ulcer
disease, gastric adeno-carcinoma
and lymphoma.⁷ It is one of the most common
infectious diseases worldwide.⁸ There is
evidence that suggests that Helicobacter pylori is a
frequent organism in dyspeptic patients,
causing peptic ulcer dyspepsia and non-ulcer
dyspepsia.⁹ The risk factors of acquiring
Helicobacter Pylori (H-Pylori) infections are poor
sanitary conditions, smoking, high salts intake,
overcrowding, number of siblings and poverty.
Developing countries have a higher
prevalence rate than developed countries 70%
vs 30%.¹⁰ Helicobacter Pylori is diagnosed by

(ITP) patients. However, Helicobacter Pylori (H-
Pylori) eradication therapy significantly
improved the mean platelet counts from $48.56 \pm$
 $21.7 \times 10^9/l$ to $94.2 \pm 26.8 \times 10^9/l$.¹⁵ The study
was planned to determine the burden of
Helicobacter Pylori infection and its association
with thrombocytopenia in patients with
dyspepsia. By its eradication, we can, not only
improve the quality of life of such patients but also
reduce the incidence of gastric carcinoma.
Secondly, Helicobacter Pylori (H-Pylori) infection
is a correctable cause of thrombocytopenia, by
eradicating this organism; we can improve
immunemediated thrombocytopenia

Methods

The study was conducted at the Department of
General Medicine, Gastroenterology and
Hematology, PIMS Islamabad, Pakistan from 20th
October 2022th April 2026 after taking
approval from the Ethical Review Committee of the
hospital held on dated: 04th February 2019 vide
letter no: 194-5/2019. Sample size was calculated
with WHO sample size calculator according to
following assumptions: Confidence
level=95%, Population proportion=60%–70%.

enzyme-linked immunosorbent assay (ELISA), stool for H-Pylori antigen, and urea breathe test.¹¹ A study done by Sardar and colleagues in Jinnah post Graduate medical college Karachi, Pakistan revealed that prevalence of Helicobacter Pylori infection is 60.6%.¹² Urban areas are affected more than rural areas 70% vs 34.3%, which is more common in unmarried college-going students. Poor sanitation and drinking unhygienic water are the other risk factors for Helicobacter Pylori (H-Pylori) infections.¹³ Idiopathic thrombocytopenic purpura is an immune-mediated destruction of platelets by the autoantibodies against the platelet antigen. It is common in women than men.¹⁴ The overall prevalence is 2.5-3.9/100,000 persons per year; being more prevalent in children than adults.¹⁵ Helicobacter Pylori (H-Pylori) stool antigen was

Absolute precision = 9%. The total sample size was 275 patients. Non-probability consecutive sampling is used. All patients of either sex (male or female) or any age with the signs and symptoms of dyspepsia having immune thrombocytopenia with platelets count of less than 140,000, presenting through Gastro/Medicine OPD, wards, and emergency and admitted to hospital were included in the study. Those patients having hepatitis A virus infection (HAV), hepatitis B virus infection (HBV), hepatitis C virus infection (HCV), Human immunodeficiency virus infection (HIV), systemic lupus erythematosus (SLE), Alcohol addicts, on drugs like non-steroidal anti-inflammatory drugs (NSAIDs), Steroids, proton pump inhibitors (PPIs), chronic renal, hepatic failure, and pregnancy were excluded from the study. Data was collected on a specially designed proforma. Informed consent was taken from the patients fulfilling inclusion



GLOBAL HEALTH & MEDICINE

ISSN / eISSN: 2434-9186 / 2434-9194

Volume 06, Issue 03.111-122

<https://ghsjournal.com/>



criteria 275 patients with dyspepsia symptoms having immunethrombocytopenia with platelets count of less than 140,000, presenting through Gastroenterology/Medicine departments of Pakistan Institute of Medical Sciences (PIMS) who fulfilled the inclusion and exclusion criteria were enrolled in the study. After collecting baseline information from patients, presenting complaints, history and signs, symptoms were recorded. Renal function test (RFTs) and other baseline tests like complete blood picture to see the platelets count were sent to the hospital laboratory. Stool sample was taken in a specifically designed disposable plastic bottle. Samples were sent to the specified laboratory for testing of Helicobacter pylori antigen in the stool. The slides of the stool sample were made. Helicobacter Pylori (H-Pylori) antigen is detected by polymerase chain reaction (PCR).

Data was entered in computer using SPSS version 22 (a statistical software) for analysis. Descriptive analysis was used for measuring mean, standard deviation, median and ranges for continuous variables like age, hemoglobin, Urea and Creatinine. Frequencies and percentages were recorded from categorical variables like sex, presenting complaints, and H-Pylori diagnosis. Results were described and also presented in the form of tables and graphs.

Results

In our study 275 patients presenting with sign and symptoms of dyspepsia having throm-

40.02±14.4 years ranging from 14 to 95 years. 75% were above 30 years of age. While about 50% were above 41 years of age. Female gender was predominant 61.3% proportion compared to males 38.7% in the current study. The presenting complaints of patients were retrosternal burning in 102 (74.4%) cases, bloating 89 (64.9%) cases, pain and/or discomfort in upper abdomen in 68 (49.6%) and water brash was present in 104 (37.9%). The chemistry results of the study patients were as the average serum urea was 31.9±7.3 mg/dl in the study patients ranging from 3.0 to 48.0 mg/dl. The mean + SD serum creatinine level was 0.70 + 0.26 in the study patients ranging from 0.2 to 1.2 mg/dl. The majority of the study patients had serum urea of up to 30 mg/dl, while almost 70% of the study cases had serum creatinine levels between 0.4 and 0.9 mg/dl. The final diagnosis of h-pylori in study patients was done on the basis of stool for h-pylori antigen investigation. The frequency of h-pylori in the current study was 177 (64.2%). In our study we found out that females 128 (72.7%) were more likely to have h-pylori compared to males 47 (27.3%) (figure.1). The distribution of h-pylori cases according to age is equal in all age groups in the current study. 54 (30.5%) patients with H-pylori infections have thrombocytopenia. (Table-1 and 2).

Discussion

Helicobacter pylori (H-pylori) infection is nowadays recognized as one of the most common complications, which occur in 25% of

Table-1: Descriptive Baseline Statistics (n=275)

	Mean ± S.D	Min – Max	86
Age (years)	40.02 ± 14.4	14-95	
Urea (mg/dl)	31.9 ± 7.3		
Creatinine (mg/dl)	0.70 ± 0.26		

3 – 48

0.2 – 1.2

Table-2: Frequency of Thrombocytopenia in H-Pylori (n = 275)

H-Pylori Infection (n = 177)	Thrombocytopenia	
	Yes	No
	(30.5%)	(69.5%)

54

No
123




Fig.1:Frequency of H-pylori Positive patients

the adult population and are responsible for dyspepsia, which occurs in 25% of the adult population and accounts for 5% of general clinic visits. Dyspepsia is the term used for acute, chronic or recurrent one of the following four symptoms: epigastric discomfort or pain, postprandial upper abdomen fullness, early satiety, bloating, belching, and nausea, retching or vomiting without structural diseases.^{16,17}

H. pylori infection associated with immune thrombocytopenic purpura (ITP). Many observational studies found a good platelet response in ITP patients treated with H. pylori

eradication.¹⁸ A randomized controlled trial revealed that H. pylori eradication resulted in a significant platelet response in patients affected by ITP.¹⁹

Common causes of dyspepsia are gastroesophageal reflux disease and peptic ulcer disease.²⁰ Serious but rare causes are gastric carcinomas must be considered.²¹ The alarming symptoms for dyspepsia are; gastrointestinal bleeding, progressive weight loss, dysphagia, persistent vomiting and iron

from 58.2% (in 1990-2010) to 43.1% (in 2011-2022). There is much reduction in prevalence when compared to our study.²⁴ The average presenting age of our study patients was 40.0 ± 14.4 years ranging from 14 to 95 years. There is a slight variation in different geographical areas. Namyalo and his colleagues showed that prevalence of Helicobacter pylori infection was higher at 39.4% in young 19–35 years than in older age.

It may be due to work-related stress.²⁴⁻²⁶

In our study, the female gender was predominant with 61.3% proportion and female to male ratio of 1.5: 1. While in Agarwal's study, the positivity of Helicobacter pylori infections in the female to male ratio was 1–1.7.²⁶ Another primary objective was to see Helicobacter pylori infection association with thrombocytopenia.

Limitations of the study include a small sample size; a large sample size would be a better indicator, and the inaccessibility of data about bacterial strain identification.

Conclusion

Our findings validate previous reports that H.

deficiency anemia. It needs urgent investigation and management.²² In our study the incidence of h-pylori in dyspepsia patients was 64.2%. Compared to our findings previous studies showed H. pylori infection with variable rates. A retrospective study, by Dedino et al. 2012-2016. Helicobacter pylori prevalence

pylori infection is associated with dyspepsia and thrombocytopenia. Our findings are further validated by the evidence that after the Helicobacter eradication therapy, there is marked improvement in platelets count (Thrombocytopenia is settled) **Acknowledgment:** We thank all of our patients for their participation in this study and having trust on us was 51.5%.²³ Sardar Mand colleagues from Pakistan revealed the prevalence rate 60.6%.¹² Urban affected more than rural people 70% vs 34.3%, more common in unmarried adolescent.¹³ The rates of H. pylori infection are greater than our findings of 64.2%. Choi et al. showed that the prevalence of Helicobacter. Pylori infections are decreased

to have their secret information as promised not to be disclosed

Conflict of Interest: The authors declare no conflict of interest **Grant**

Support and Financial Disclosure: None

REFERENCES

1. VandenHoute K, Carbone F, Goelen N, Schol J, Masuy K, Arts J, et al. Effect of Rome IV definitions of functional dyspepsia subgroups in secondary care. *Clinical Gastroenterology and Hepatology*. 2021;19: 1620-26. doi:10.1016/j.cgh.2020.06.043
2. De Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgheri G, Albano E, et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. *Annals of Gastroenterology*. 2018;31:639-48. doi:

- 10.20524/aog.2018.0314
3. Kim SE, Kim N, Lee JY, Park KS, Shin JE, Nam K, et al. Prevalence and risk factors of functional dyspepsia in health check-up population: a nationwide multi-center prospective study. *Journal of Neurogastroenterology and Motility*. 2018; 24: 603-13. doi: 10.5056/jnm18068
 4. Kim YA, Cho YJ, Kwak SJ. The association between *Helicobacter pylori* infection and irritable bowel syndrome: a meta-analysis. *International Journal of Environmental Research and Public Health*. 2020; 17: 2524-33. doi: 10.3390/ijerph17072524
 5. Kim YS, Kim N. Functional dyspepsia: a narrative review with a focus on sex-gender differences. *Neurogastroenterology and Motility*. 2020; 26: 322-34. doi: 10.5056/jnm20026
 6. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. *Lancet*. 2020; 396: 1689-1702. doi: 10.1016/S0140-6736(20)30469-4.
 7. Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. *Helicobacter pylori* and Gastric Cancer: Pathogenetic mechanisms. *International Journal of Molecular Sciences*. 2023; 24: 2895-8. doi: 10.3390/ijms24032895
 8. Ofori EG, Adinortey CA, Bockarie AS, Kyei F, Tagoe EA, Adinortey MB. *Helicobacter pylori* infection, virulence genes' distribution and accompanying clinical outcomes: The West Africa situation. *BioMed research international*. 2019; 2019: 7312908. doi: 10.1155/2019/7312908
 9. Bello A, Umar A, Borodo M. Prevalence and risk factors for *Helicobacter pylori* infection in gastroduodenal diseases in Kano, Nigeria. *African Journal of Medical and Health Sciences*. 2018; 17: 41-6. doi: 10.4103/ajmhs.ajmhs_36_17
 10. Basílio IL, Catão MD, Carvalho JD, Freire-Neto FP, Ferreira LC, Jerônimo SM. Risk factors of *Helicobacter pylori* infection in an urban community in northeast Brazil and the relationship between the infection and gastric diseases. *Revista da Sociedade Brasileira de Medicina Tropical*. 2018; 51: 183-9. doi: 10.1590/0037-8682-0412-2016
 11. Miftahussurur M. Noninvasive *Helicobacter pylori* diagnostic methods in Indonesia. *Gut and liver*. 2019; 14: 553-9. doi: 10.5009/gnl19264
 12. Sardar M, Kumar D, Aakash FN, Partab FN, Kumar S, Barkha FN, et al. Prevalence and etiology of *Helicobacter pylori* infection in dyspepsia patients: a hospital-based cross-sectional study. *Annals of Medicine and Surgery*. 2023; 85: 665-9. doi: 10.1097/MS9.000000000000120
 13. Shah SRH, Almagadam BS, Hussain A, Ahmad T, Ahmed S, Sadiqui S. Epidemiology and risk factors of

- Helicobacter pylori infection in Timergara city of Pakistan: A cross-sectional study. *Clinical Epidemiology and Global Health*. 2021; 12: 100909. doi:10.1016/j.cegh.2021.100909
14. Kim DS. Recent advances in treatments of adult immune thrombocytopenia. *Blood Research*. 2022; 57:112-19. doi:10.5045/br.2022.2022038
 15. Bussela J, Cooper N, Boccia R, Zaja F, Newland A. Immunethrombocytopenia. *Expert Review Hematology*. 2021;14:1013-25. doi:10.1080/17474086.2021.1995347
 16. Ikuse T, Toda M, Kashiwagi K, Maruyama K, Nagata M, Tokushima K, et al. Efficacy of Helicobacter pylori eradication therapy on platelet recovery in pediatric immunethrombocytopenic purpura: Case series and a systematic review. *Microorganisms*. 2020;8:1457. doi: 10.3390/microorganisms8101457
 17. Mounsey A, Barzin A, Rietz A. Functional Dyspepsia: Evaluation and Management. *Journal of American Family Physician*. 2020;101:84-8
 18. Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, et al. Extra-Gastric manifestations of Helicobacter pylori infection. *Journal of Clinical Medicine*. 2020;9:3887. doi:10.3390/jcm9123887
 19. Pezeshki SM, Saki N, Ghandali MV, Ekrami A, Avarvand AY. Effect of Helicobacter Pylori eradication on patients with ITP: A meta-analysis of studies conducted in the Middle East. *Blood Research*. 2021; 56:38-43. doi:10.5045/br.2021.2020189
 20. Kavitt RT, Lipowska AM, Anyane-Yeboah A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. *The American journal of medicine*. 2019; 132: 447-56. doi:10.1016/j.amjmed.2018.12.009
 21. Macke L, Schulz C, Malfertheiner P. The fear of gastric cancer in patients with dyspepsia: a challenge in specialist gastroenterology. *Journal of Digestive Diseases*. 2022;40:409-16. doi:10.1159/000518394
 22. Panigrahi S, Khatua CR, Mishra D, Parida PK, Singh S P. A prospective study evaluating the etiologic spectrum in patients with dysphagia in coastal

Odisha using
clinical features and endoscopy. *Journal of Digestive Endoscopy*. 2019; 10: 107-11. doi:
10.1055/s-0039-
1693286

23. Aminde JA, Dedino GA, Ngwasiri CA, Ombaku KS, Mahop Makon CA, Aminde LN. Helicobacter pylori infection among patients presenting with dyspepsia at a primary care setting in Cameroon: seroprevalence, five-year trend and predictors. *BMC infectious diseases*. 2019; 19: 30. doi:10.1186/s12879-019-3677-0
24. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK.

- Global prevalence of *Helicobacter pylori* infection between 1980 and 2022: a systematic review and meta-analysis. *The lancet Gastroenterology & hepatology*.2023;8:553-64.doi:10.1016/S2468-1253(23)00070-5
25. NamyaloE,NyakarahukaL,AfayoaM, BaziiraJ, Tamale A,KunguJM,etal.Prevalenceof*Helicobacterpylori* amongpatientswithgastrointestinaltractsymptoms : a retrospective study at selected africa air rescue (AAR)clinicsinKampala,Uganda,from2015to2019. *JournalTropical Medicine*. 2021; 2021: 9935142. doi: 10.1155/2021/9935142
26. AgarwalPK,BadkurM,AgarwalR,PatelS.Prevalence of *Helicobacter pylori* infection in upper gastro-intestinaltractdisorders(dyspepsia)patientsvisiting outpatient department of a hospital of North India. *JournalofFamilyMedicineandPrimaryCare*.2018; 7: 577-80.doi:10.4103/jfmpc.jfmpc_213_17
-